354 related articles for article (PubMed ID: 35127738)
1. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.
Chen HQ; Gong JY; Xing K; Liu MZ; Ren H; Luo JQ
Front Med (Lausanne); 2021; 8():742394. PubMed ID: 35127738
[TBL] [Abstract][Full Text] [Related]
2. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
[TBL] [Abstract][Full Text] [Related]
3. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
Jia L; Huang S; Sun B; Shang Y; Zhu C
Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254
[TBL] [Abstract][Full Text] [Related]
4. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.
Kamath S; Stringer AM; Prestidge CA; Joyce P
Expert Opin Drug Deliv; 2023; 20(10):1315-1331. PubMed ID: 37405390
[TBL] [Abstract][Full Text] [Related]
5. Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.
Arga KY; Attia H; Aziz RK
OMICS; 2024 Jan; 28(1):5-7. PubMed ID: 38190279
[TBL] [Abstract][Full Text] [Related]
6. Sexual Dimorphic Interplays Between Gut Microbiota and Antihypertensive Drugs.
Bardhan P; Yang T
Curr Hypertens Rep; 2023 Aug; 25(8):163-172. PubMed ID: 37199902
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Antihypertensive Drugs: Is Gut Microbiota the Missing Link?
Kyoung J; Atluri RR; Yang T
Hypertension; 2022 Oct; 79(10):2138-2147. PubMed ID: 35862173
[TBL] [Abstract][Full Text] [Related]
8. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.
Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA
FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628
[TBL] [Abstract][Full Text] [Related]
9. Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada M; Vila AV; Zhernakova A; Koonen DPY; Weersma RK; Touw DJ; Kuipers F; Wijmenga C; Fu J
Protein Cell; 2018 May; 9(5):432-445. PubMed ID: 29705929
[TBL] [Abstract][Full Text] [Related]
10. The Role of Gut Microbiota in Hypertension Pathogenesis and the Efficacy of Antihypertensive Drugs.
Xiong Y; Xiong Y; Zhu P; Wang Y; Yang H; Zhou R; Shu Y; Zhou H; Li Q
Curr Hypertens Rep; 2021 Sep; 23(8):40. PubMed ID: 34487269
[TBL] [Abstract][Full Text] [Related]
11. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma A; Buschmann MM; Gilbert JA
Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
[TBL] [Abstract][Full Text] [Related]
12. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs.
Choi MS; Yu JS; Yoo HH; Kim DH
Pharmacol Res; 2018 Apr; 130():164-171. PubMed ID: 29391236
[TBL] [Abstract][Full Text] [Related]
13. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
[TBL] [Abstract][Full Text] [Related]
14. Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?
Kaźmierczak-Siedlecka K; Bulman N; Ulasiński P; Sobocki BK; Połom K; Marano L; Kalinowski L; Skonieczna-Żydecka K
Gut Microbes; 2023 Dec; 15(2):2281017. PubMed ID: 37985748
[TBL] [Abstract][Full Text] [Related]
15. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes.
Saad R; Rizkallah MR; Aziz RK
Gut Pathog; 2012 Nov; 4(1):16. PubMed ID: 23194438
[TBL] [Abstract][Full Text] [Related]
16. Drug-microbiota interactions: an emerging priority for precision medicine.
Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
[TBL] [Abstract][Full Text] [Related]
17. Invited review: Effect of antihypertensive fermented milks on gut microbiota.
Beltrán-Barrientos LM; García HS; Hernández-Mendoza A; González-Córdova AF; Vallejo-Cordoba B
J Dairy Sci; 2021 Apr; 104(4):3779-3788. PubMed ID: 33752288
[TBL] [Abstract][Full Text] [Related]
18. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects.
Leigh SJ; Lynch CMK; Bird BRH; Griffin BT; Cryan JF; Clarke G
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):5-26. PubMed ID: 35176217
[TBL] [Abstract][Full Text] [Related]
20. Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.
Leardini D; Venturelli F; Baccelli F; Cerasi S; Muratore E; Brigidi P; Pession A; Prete A; Masetti R
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
